1,3,5-Triazine-2,4,6-Triamine Compound or Pharmaceutical Acceptable Salt Thereof, and Pharmaceutical Composition Comprising the Same
AssigneesHanall Pharmaceutical Company, Ltd., Korea Research Institute of Chemical Technology
InventorsHyae Gyeong Cheon, Kwang-Rok Kim, Sang Dal Rhee, Won Hoon Jung, Jong-Cheol Lee, Sung Wuk Kim, Sung Soo Jun
Life of this patent
Estimating the term…
Abstract
Disclosed herein are a 1,3,5-triazine-2,4,6-triamine compound or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a composition for preventing or treating metabolic syndromes, diabetes, or cancers with deletion of P53 gene, which comprises the same.
Claims10
A 1,3,5-triazine-2,4,6-triamine compound of Formula 1, or a pharmaceutically acceptable salt thereof:
- wherein R1 and R2 each independently represents hydrogen or a (C1-C5)-alkyl;
- and
- R3 and R4 each independently represents hydrogen, a (C1-C7)-alkyl, a (C3-C7)cycloalkyl, a phenyl, a phenyl-(C1-C3)-alkyl, a naphthyl, a napthyl-(C1-C3)alkyl, a (C6-C13)aryl, (C3-C7)heterocycloalkyl, a (C3-C7)-heterocycloalkyl-(C1-C6)alkyl, a heteroaryl or heteroaryl-(C1-C6)-alkyl, or
- R3 and R4, together with nitrogen to which they are attached, form a (C3-C8)heterocycloalkyl,
- wherein the phenyl or naphthyl may be substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a nitro group, a cyano group, a (C1-C6)alkyl group, a (C1-C6)haloalkyl group, a (C3-C6)cycloalkyl group, a (C6-C10)aryl group, a (C6-C10)aryloxy group, a (C1-C6)alkoxy group, a (C1-C6)haloalkoxy group, a (C3-C6)cycloalkyloxy group, a (C1-C7)alkanoyl group, a carboxyl group, a carbamoyl group, an alkylamino group, a (C2-C7)sulfonic acid group, a sulfonamido group, and a (C1-C6)alkylthio group;
- with proviso that when R1 and R2 are hydrogen, R3 and R4 are not (C1-C7)alkyl.
4-7. (canceled)
A method for preventing or treating a metabolic syndrome, which comprises the step of administering a pharmaceutical composition comprising the 1,3,5-triazine-2,4,6-triamine compound of Formula 1 or pharmaceutically acceptable salt:
- wherein R1 and R2 each independently represents hydrogen or a (C1-C5)alkyl;
- and
- R3 and R4 each independently represents hydrogen, a (C1-C7)alkyl, a (C3-C7)cycloalkyl, a phenyl, a phenyl(C1-C3)alkyl, a naphthyl, a napthyl(C1-C3)alkyl, a (C6-C13)aryl, (C3-C7)heterocycloalkyl, a (C3-C7)heterocycloalkyl(C1-C6)alkyl, a heteroaryl or heteroaryl(C1-C6)alkyl, or
- R3 and R4, together with nitrogen to which they are attached, form a (C3-C8)heterocycloalkyl,
- wherein the phenyl or naphthyl may be substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a nitro group, a cyano group, a (C1-C6)alkyl group, a (C1-C6)haloalkyl group, a (C3-C6)cycloalkyl group, a (C6-C10)aryl group, a (C6-C10)aryloxy group, a (C1-C6)alkoxy group, a (C1-C6)haloalkoxy group, a (C3-C6)cycloalkyloxy group, a (C1-C7) alkanoyl group, a carboxyl group, a carbamoyl group, an alkylamino group, a (C2-C7)sulfonic acid group, a sulfonamido group, and a (C1-C6)alkylthio group.
A method for preventing or treating diabetes, which comprises the step of administering a pharmaceutical composition comprising the 1,3,5-triazine-2,4,6-triamine compound of Formula 1 or pharmaceutically acceptable salt:
- wherein R1 and R2 each independently represents hydrogen or a (C1-C5)alkyl;
- and
- R3 and R4 each independently represents hydrogen, a (C1-C7)alkyl, a (C3-C7)cycloalkyl, a phenyl, a phenyl(C1-C3)alkyl, a naphthyl, a napthyl(C1-C3)alkyl, a (C6-C13)aryl, (C3-C7)heterocycloalkyl, a (C3-C7)heterocycloalkyl(C1-C6)alkyl, a heteroaryl or heteroaryl(C1-C6)alkyl, or
- R3 and R4, together with nitrogen to which they are attached, form a (C3-C8)heterocycloalkyl,
- wherein the phenyl or naphthyl may be substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a nitro group, a cyano group, a (C1-C6)alkyl group, a (C1-C6)haloalkyl group, a (C3-C6)cycloalkyl group, a (C6-C10)aryl group, a (C6-C10)aryloxy group, a (C1-C6)alkoxy group, a (C1-C6)haloalkoxy group, a (C3-C6)cycloalkyloxy group, a (C1-C7)alkanoyl group, a carboxyl group, a carbamoyl group, an alkylamino group, a (C2-C7)sulfonic acid group, a sulfonamido group, and a (C1-C6)alkylthio group.
A method for preventing or treating cancer, which comprises the step of administering a pharmaceutical composition comprising the 1,3,5-triazine-2,4,6-triamine compound of Formula 1 or pharmaceutically acceptable salt:
- wherein R1 and R2 each independently represents hydrogen or a (C1-C5)alkyl;
- and
- R3 and R4 each independently represents hydrogen, a (C1-C7)alkyl, a (C3-C7)cycloalkyl, a phenyl, a phenyl(C1-C3)alkyl, a naphthyl, a napthyl(C1-C3)alkyl, a (C6-C13)aryl, (C3-C7)heterocycloalkyl, a (C3-C7)heterocycloalkyl(C1-C6)alkyl, a heteroaryl or heteroaryl(C1-C6)alkyl, or
- R3 and R4, together with nitrogen to which they are attached, form a (C3-C8)heterocycloalkyl,
- wherein the phenyl or naphthyl may be substituted with a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a nitro group, a cyano group, a (C1-C6)alkyl group, a (C1-C6)haloalkyl group, a (C3-C6)cycloalkyl group, a (C6-C10)aryl group, a (C6-C10)aryloxy group, a (C1-C6)alkoxy group, a (C1-C6) haloalkoxy group, a (C3-C6)cycloalkyloxy group, a (C1-C7)alkanoyl group, a carboxyl group, a carbamoyl group, an alkylamino group, a (C2-C7)sulfonic acid group, a sulfonamido group, and a (C1-C6)alkylthio group.
Dependencies are inferred from the claim text.